-
AI in Evidence Synthesis: Are the Robots Taking Over?
-
July 16-17: Practical Applications of Large Language Models for Real-World Evidence Generation and HEOR - Virtual
-
Using RWE for Label Expansion From The Health System Perspective
-
HTA in Pluralistic Healthcare Systems: A Global Perspective
-
Evolving RWE Standards Under IRA & JCA: Implications for Asia's HTA
-
Fit-for-Purpose RWD: An Integral Part of Evidence Planning
-
September 10-11: Communicating HEOR for Maximum Impact, Influence, and Understanding - Virtual
-
Why Serve on the ISPOR Board? Hear From ISPOR Leaders
-
Unlocking Success: Overcoming Cell & Gene Therapy Challenges With RWE
-
September 28: Causal Inference and Causal Estimands From Target Trial Emulations Using Evidence From Real-World Observational Studies and Clinical Trials - In Person at ISPOR Real-World Evidence Summit 2025
-
September 28: Critical Steps to Construct a Budget Impact Analysis - In Person at ISPOR Real-World Evidence Summit 2025
-
September 28: Health Technology Assessment for Rare Diseases - In Person at ISPOR Real-World Evidence Summit 2025
-
September 28: Introduction to Applied Generative AI for HEOR - In Person at ISPOR Real-World Evidence Summit 2025
-
Novel Study Design to Maximize Patient Follow-Up in Retrospective RWE Research
-
The Value of ECAs for Regulatory and HTA Evidence Needs
-
Defining Patient-Centered Access to Improve Health Outcomes
-
Navigating the US Federal Data Landscape of RWD Availability
-
October 13-16: Introduction to Health Economics and Outcomes Research - Virtual
-
How to Develop Compelling Session Proposals for ISPOR Conferences
-
The Case for Integrated RWE Generation Across the Product Lifecycle
